Lobe Sciences Ltd.
LOBE
CNSX
| 11/30/2024 | 08/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 62.57% | 1.14% | |||
| Depreciation & Amortization | -- | -100.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 57.83% | -31.74% | |||
| Operating Income | -57.83% | 31.74% | |||
| Income Before Tax | 71.51% | -552.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 71.84% | -559.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 71.84% | -559.90% | |||
| EBIT | -57.83% | 31.74% | |||
| EBITDA | -52.62% | 28.32% | |||
| EPS Basic | 71.90% | -505.00% | |||
| Normalized Basic EPS | -40.00% | 21.05% | |||
| EPS Diluted | 71.90% | -505.00% | |||
| Normalized Diluted EPS | -40.00% | 21.05% | |||
| Average Basic Shares Outstanding | 1.63% | 7.64% | |||
| Average Diluted Shares Outstanding | 1.63% | 7.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||